Abstract
The basis for the excess mortality with age after acute myocardial infarction (AMI) is not clear, nor is it known whether the mode of death is altered with age. Age-related factors predictive of mortality and age-related mechanisms of the 333 deaths were examined in 2,466 patients who were enrolled in a placebo-controlled trial to determine the effect of diltiazem on mortality and reinfarction after AMI. There were 3 age groups with increasing mortality rates: ages 25 to 49 (n = 499), 50 to 64 (n = 1,228) and 65 to 75 years (n = 739). There was a significant age-related increase in the proportion of patients with baseline risk factors. These baseline characteristics did not differ by treatment (placebo vs diltiazem). However, multi-variate survivorship analysis still identified age as an independent risk factor for cardiac death. The proportion of arrhythmic and myocardial failure deaths did not differ by treatment or age group.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 559-566 |
| Number of pages | 8 |
| Journal | The American journal of cardiology |
| Volume | 65 |
| Issue number | 9 |
| DOIs | |
| State | Published - Mar 1 1990 |
Funding
The basis for the excess mortality with age after acute myocardial infarction (AM) is not clear, nor is it known whether the mode of death is altered ivith age. Age-related factors predictive of mortality and age+elated mechanisms of the 333 deaths were examined in 2,466 patiis who were enrolled in a placebo-controlled trial to determine the effect of diltlazem on mortality and reinfarction after AMI. There were 3 age groups with increasing mortalii rates: ages 25 to 49 (n = 4SS), 50 to 64 (n = 1,228) and 65 to 75 years (n = 739). Tltere was a signiftcant age-related increase in the proportion of patients with baseline risk factors. These baseline characterlstfcs did not differ by treatment (placebo vs diltlazem). However, multi-varlate survivorship analysis still identlfted age as an independent risk factor for card& death. The proportion of arrhythmic and myocardial failure deaths did not differ by treatment or age group. (Am J Cardioi 1990;65:559-566) From the Section of Cardiology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona. This study was supported in part by grants from Marion Laboratories, Kansas City, Missouri, The Flinn Foundation, Phoenix, Arizona, and the Gustavus and Louise Pfeiffer Research Foundation, Santa Monica, California. Manuscript received July 3 1, 1989; revised manuscript received October 27, 1989, and accepted October 28.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine